Circulating tumour cells in breast cancer

Natalia Krawczyk; Malgorzata Banys; Andreas Hartkopf; Carsten Hagenbeck; Carola Melcher; Tanja Fehm

doi:10.3332/ecancer.2013.352

Circulating tumour cells in breast cancer

Natalia Krawczyk, Malgorzata Banys, Andreas Hartkopf, Carsten Hagenbeck, Carola Melcher, Tanja Fehm

Department of Gynecology and Obstetrics

14 Citations (Scopus)

Abstract

Evaluation of isolated tumour cells in bone marrow (BM) and peripheral blood has become a major focus of translational cancer research. The presence of disseminated tumour cells in BM is a common phenomenon observed in 30-40% of primary breast cancer patients and independently predicts reduced clinical outcome. The detection of circulating tumour cells (CTCs) in blood might become a desired alternative to the invasive and painful BM biopsy. Recent clinical trials confirmed the feasibility of CTC detection as a robust and reproducible parameter for prognostication in both adjuvant and metastatic setting. The characterisation of CTCs might become an important biomarker for therapy monitoring and help to identify specific targets for novel therapeutic strategies. Copyright:

Original language	English
Article number	352
Journal	ecancermedicalscience
Volume	7
Issue number	1
DOIs	https://doi.org/10.3332/ecancer.2013.352
Publication status	Published - 19.09.2013

Funding

We acknowledge the support of the Breast Cancer Campaign (grant 2001/243) and the Breast Cancer Research Trust. We thank Lila Zabaglo for her help in preparation of this review.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.3332/ecancer.2013.352

Cite this

@article{9c15857dda2041cb9e255151c55ae5b4,

title = "Circulating tumour cells in breast cancer",

abstract = "Evaluation of isolated tumour cells in bone marrow (BM) and peripheral blood has become a major focus of translational cancer research. The presence of disseminated tumour cells in BM is a common phenomenon observed in 30-40\% of primary breast cancer patients and independently predicts reduced clinical outcome. The detection of circulating tumour cells (CTCs) in blood might become a desired alternative to the invasive and painful BM biopsy. Recent clinical trials confirmed the feasibility of CTC detection as a robust and reproducible parameter for prognostication in both adjuvant and metastatic setting. The characterisation of CTCs might become an important biomarker for therapy monitoring and help to identify specific targets for novel therapeutic strategies. Copyright:",

author = "Natalia Krawczyk and Malgorzata Banys and Andreas Hartkopf and Carsten Hagenbeck and Carola Melcher and Tanja Fehm",

note = "Funding Information: We acknowledge the support of the Breast Cancer Campaign (grant 2001/243) and the Breast Cancer Research Trust. We thank Lila Zabaglo for her help in preparation of this review. ",

year = "2013",

month = sep,

day = "19",

doi = "10.3332/ecancer.2013.352",

language = "English",

volume = "7",

journal = "ecancermedicalscience",

issn = "1754-6605",

publisher = "ecancer Global Foundation",

number = "1",

}

TY - JOUR

T1 - Circulating tumour cells in breast cancer

AU - Krawczyk, Natalia

AU - Banys, Malgorzata

AU - Hartkopf, Andreas

AU - Hagenbeck, Carsten

AU - Melcher, Carola

AU - Fehm, Tanja

N1 - Funding Information: We acknowledge the support of the Breast Cancer Campaign (grant 2001/243) and the Breast Cancer Research Trust. We thank Lila Zabaglo for her help in preparation of this review.

PY - 2013/9/19

Y1 - 2013/9/19

N2 - Evaluation of isolated tumour cells in bone marrow (BM) and peripheral blood has become a major focus of translational cancer research. The presence of disseminated tumour cells in BM is a common phenomenon observed in 30-40% of primary breast cancer patients and independently predicts reduced clinical outcome. The detection of circulating tumour cells (CTCs) in blood might become a desired alternative to the invasive and painful BM biopsy. Recent clinical trials confirmed the feasibility of CTC detection as a robust and reproducible parameter for prognostication in both adjuvant and metastatic setting. The characterisation of CTCs might become an important biomarker for therapy monitoring and help to identify specific targets for novel therapeutic strategies. Copyright:

AB - Evaluation of isolated tumour cells in bone marrow (BM) and peripheral blood has become a major focus of translational cancer research. The presence of disseminated tumour cells in BM is a common phenomenon observed in 30-40% of primary breast cancer patients and independently predicts reduced clinical outcome. The detection of circulating tumour cells (CTCs) in blood might become a desired alternative to the invasive and painful BM biopsy. Recent clinical trials confirmed the feasibility of CTC detection as a robust and reproducible parameter for prognostication in both adjuvant and metastatic setting. The characterisation of CTCs might become an important biomarker for therapy monitoring and help to identify specific targets for novel therapeutic strategies. Copyright:

UR - https://www.scopus.com/pages/publications/84887831899

U2 - 10.3332/ecancer.2013.352

DO - 10.3332/ecancer.2013.352

M3 - Scientific review articles

AN - SCOPUS:84887831899

SN - 1754-6605

VL - 7

JO - ecancermedicalscience

JF - ecancermedicalscience

IS - 1

M1 - 352

ER -

Circulating tumour cells in breast cancer

Abstract

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this